Ingelheim, Germany, 25 July, 2012 – Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
Jentadueto® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe
New treatment will provide a single tablet option for adults who need to reduce their blood sugar - For Non-U.S. and Non-UK Media
Jul 24, 2012
Latest in Home
Stanley Black & Decker to Invest $1B in Its U.S. Operations
August 14, 2026
GM Reveals $4.5B Supply Chain Shield for Emergencies
August 14, 2026
